202 related articles for article (PubMed ID: 20961309)
41. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
Leppänen VM; Prota AE; Jeltsch M; Anisimov A; Kalkkinen N; Strandin T; Lankinen H; Goldman A; Ballmer-Hofer K; Alitalo K
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2425-30. PubMed ID: 20145116
[TBL] [Abstract][Full Text] [Related]
42. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin.
Enholm B; Karpanen T; Jeltsch M; Kubo H; Stenback F; Prevo R; Jackson DG; Yla-Herttuala S; Alitalo K
Circ Res; 2001 Mar; 88(6):623-9. PubMed ID: 11282897
[TBL] [Abstract][Full Text] [Related]
43. Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway.
Huang B; Lu Y; Gui M; Guan J; Lin M; Zhao J; Mao Q; Lin J
Biomed Pharmacother; 2021 May; 137():111331. PubMed ID: 33578235
[TBL] [Abstract][Full Text] [Related]
44. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.
Jeltsch M; Karpanen T; Strandin T; Aho K; Lankinen H; Alitalo K
J Biol Chem; 2006 Apr; 281(17):12187-95. PubMed ID: 16505489
[TBL] [Abstract][Full Text] [Related]
45. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis.
Shin JW; Huggenberger R; Detmar M
Blood; 2008 Sep; 112(6):2318-26. PubMed ID: 18614759
[TBL] [Abstract][Full Text] [Related]
46. Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases.
Wang XL; Fang JP; Tang RY; Chen XM
BMC Cancer; 2010 Jun; 10():299. PubMed ID: 20565772
[TBL] [Abstract][Full Text] [Related]
47. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
Onofri C; Losa M; Uhl E; Stalla GK; Renner U
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):152-7. PubMed ID: 18205092
[TBL] [Abstract][Full Text] [Related]
49. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
[TBL] [Abstract][Full Text] [Related]
50. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis.
Kajiya K; Sawane M; Huggenberger R; Detmar M
J Invest Dermatol; 2009 May; 129(5):1292-8. PubMed ID: 19005491
[TBL] [Abstract][Full Text] [Related]
51. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.
Cursiefen C; Chen L; Borges LP; Jackson D; Cao J; Radziejewski C; D'Amore PA; Dana MR; Wiegand SJ; Streilein JW
J Clin Invest; 2004 Apr; 113(7):1040-50. PubMed ID: 15057311
[TBL] [Abstract][Full Text] [Related]
52. Leishmania major Infection-Induced VEGF-A/VEGFR-2 Signaling Promotes Lymphangiogenesis That Controls Disease.
Weinkopff T; Konradt C; Christian DA; Discher DE; Hunter CA; Scott P
J Immunol; 2016 Sep; 197(5):1823-31. PubMed ID: 27474074
[TBL] [Abstract][Full Text] [Related]
53. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
54. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM
Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927
[TBL] [Abstract][Full Text] [Related]
55. Modulation of Receptor Tyrosine Kinase Activity through Alternative Splicing of Ligands and Receptors in the VEGF-A/VEGFR Axis.
Stevens M; Oltean S
Cells; 2019 Mar; 8(4):. PubMed ID: 30925751
[TBL] [Abstract][Full Text] [Related]
56. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.
Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S
Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579
[TBL] [Abstract][Full Text] [Related]
57. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.
Goldman J; Rutkowski JM; Shields JD; Pasquier MC; Cui Y; Schmökel HG; Willey S; Hicklin DJ; Pytowski B; Swartz MA
FASEB J; 2007 Apr; 21(4):1003-12. PubMed ID: 17210781
[TBL] [Abstract][Full Text] [Related]
58. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis.
Burton JB; Priceman SJ; Sung JL; Brakenhielm E; An DS; Pytowski B; Alitalo K; Wu L
Cancer Res; 2008 Oct; 68(19):7828-37. PubMed ID: 18829538
[TBL] [Abstract][Full Text] [Related]
59. Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro.
Tille JC; Wang X; Lipson KE; McMahon G; Ferrara N; Zhu Z; Hicklin DJ; Sleeman JP; Eriksson U; Alitalo K; Pepper MS
Exp Cell Res; 2003 May; 285(2):286-98. PubMed ID: 12706123
[TBL] [Abstract][Full Text] [Related]
60. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.
Björndahl MA; Cao R; Burton JB; Brakenhielm E; Religa P; Galter D; Wu L; Cao Y
Cancer Res; 2005 Oct; 65(20):9261-8. PubMed ID: 16230387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
